| Autor: |
Nechifor-Boilă IA; Department of Anatomy and Embryology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu-Mureș, 540142 Târgu-Mures, Romania.; Department of Urology, Mureș County Hospital, 540142 Târgu-Mures, Romania., Loghin A; Department of Histology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu-Mureș, 540142 Târgu-Mures, Romania.; Department of Pathology, Mureș County Hospital, 540011 Târgu-Mureș, Romania., Nechifor-Boilă A; Department of Histology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu-Mureș, 540142 Târgu-Mures, Romania.; Department of Pathology, Mureș County Hospital, 540011 Târgu-Mureș, Romania., Decaussin-Petrucci M; Centre Hospitalier Lyon Sud, Department of Pathology, Universite Claude Bernard Lyon 1, 69310 Pierre-Bénite, France., Voidăzan S; Department of Epidemiology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu-Mureș, 540142 Târgu-Mures, Romania., Chibelean BC; Department of Urology, Mureș County Hospital, 540142 Târgu-Mures, Romania., Martha O; Department of Urology, Mureș County Hospital, 540142 Târgu-Mures, Romania., Borda A; Department of Histology, George Emil Palade University of Medicine, Pharmacy, Science and Technology of Târgu-Mureș, 540142 Târgu-Mures, Romania.; Department of Pathology, Emergency Mureș County Hospital, 540136 Târgu Mureș, Romania. |
| Abstrakt: |
In the present study, we analyzed Programmed Death Ligand-1 (PD-L1) expression in radical cystectomy (RC) specimens from patients with muscle-invasive urothelial carcinoma (UC), in order to assess any correlations with specific clinicopathological features and its potential prognostic value. A multi-institutional study was performed within the departments of urology and pathology at the Mureș County Hospital, Romania, and Centre Hospitalier Lyon Sud, France. Sixty-nine patients with MIBC were included, for whom tumor histology (conventional versus histological variant/differentiation), tumor extension (T), lymph node involvement (N), and distant metastases (M) were recorded. PD-L1 immunostaining was performed using the 22C3 clone and was interpreted using the combined positive score (CPS) as recommended (Dako Agilent, Santa Clara, CA, USA). Positive PD-L1 immunostaining was more prevalent among UCs with squamous differentiation compared to conventional UCs and trended towards an improved OS ( p = 0.366). We found the T stage to be a risk factor for poor survival in PD-L1-positive patients (HR 2.9, p = 0.021), along with the N stage in PD-L1-negative patients (HR 1.98, p = 0.007). No other clinicopathological factor was found to be significantly associated with PD-L1 positivity. Thus, we confirm the need for PD-L1 immunostaining prior to initiating immune checkpoint inhibitor therapy for a more accurate assessment of the patients' chances of responding to treatment. |
